Your shopping cart is currently empty

B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $68 | In Stock | In Stock | |
| 5 mg | $168 | In Stock | In Stock | |
| 10 mg | $247 | In Stock | In Stock | |
| 25 mg | $418 | In Stock | In Stock | |
| 50 mg | $612 | In Stock | In Stock | |
| 100 mg | $786 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $39 | In Stock | In Stock |
| Description | B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins. |
| Targets&IC50 | NF-κB-inducing kinase (NIK):4.2 nM (Ki) |
| In vitro | B022 treatment of Hepa1 cells (0 μM, 0.5 μM, 5 μM; 12 hours) can suppress NIK-induced p52 formation in a dose-dependent manner[1]. |
| In vivo | In STOP-NIK male mice (8 weeks old) infected with Ad-cre, B022 (30 mg/kg; intravenous injection; twice daily; for 10 days) completely prevents the lethal effects induced by abnormally high levels of hepatic NIK in mice. It inhibits the majority of the deteriorating effects caused by aberrant activation of hepatic NIK[1]. |
| Molecular Weight | 397.88 |
| Formula | C19H16ClN5OS |
| Cas No. | 1202764-53-1 |
| Smiles | CC(O)(C#Cc1ccc2CCN(c2c1)c1nc(N)ncc1Cl)c1nccs1 |
| Relative Density. | 1.53 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (502.66 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.57 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.